Multiple Myeloma (MM)
Conditions
Interventions
Daratumumab therapy group:Nil
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients (aged >=18 years); 2. Diagnosed as MM; 3. Patients who started daratumumab treatment after August 01, 2019 and will continue to receive daratumumab treatment at the beginning of the study according to the judgment of the doctor of the research center; or patients who, at the discretion of the physician at the study site, will start receiving daratumumab after the start of the study; 4. Patients and/or their legal representatives (if applicable) understand and voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have been diagnosed with other cancers before MM diagnosis, except those who are considered to be cured for more than 3 years before enrollment, and have a minimal risk of recurrence of skin squamous cell carcinoma and basal cell carcinoma, cervical or breast carcinoma in situ; 2. The patient has received at least 4 lines of prior therapy before starting daratumumab-based therapy; 3. Patients who are currently participating in other investigative studies or clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival ;Time after tumor treatment to tumor remission;Tumor remission duration;Duration of treatment with daratumumab;Reasons for daratumumab dose reduction, interruption, and discontinuation of therapy; | — |
Countries
China
Contacts
Public ContactNiu Ting
Outcome results
None listed